Abstract: According to an example aspect of the present invention, there is provided an improved method for screening of asymptomatic and symptomatic subjects with Helicobacter pylori infection, atrophic gastritis with related risks and/or disturbed gastric function based on whole blood samples, sample collection time and sample storage temperature, as well as relevant biomarker content analysis.

Abstract: The present invention concerns a non-toxic solid pharmaceutical composition for oral administration, containing one or more cysteine compounds from the group of L-cysteine, D-cysteine and N-acetyl cysteine, combined with one or more additional active agents, at least one of which being selected from cystine, glutathione and methionine, the composition further containing one or more pharmaceutical additives. Further, the invention concerns a method for reducing the incidence of severe headaches, particularly migraine and/or cluster headaches.

Abstract: The present invention relates to a cysteine releasing pharmaceutical preparation(s) for novel use in preventing and/or treating alcohol flushing and alcohol induced hypersensitivity reactions. Additionally, the invention relates to a method for eliminating histamine releasing effect of locally formed acetaldehyde in the digestive tract.

Abstract: The object of the invention is the use of compounds comprising one or more free sulphlydryl or amino groups for preparing a pharmaceutical composition for locally binding acetaldehyde in saliva, the stomach or the large intestine, and pharmaceutical compositions comprising the said compounds.

Abstract: The present invention relates to a method for examining a person having symptoms and/or biomarkers indicating an autoimmune disease for the presence of atrophic gastritis. The biomarker combination, which diagnoses atrophic gastritis, acts also as a part of a biomarker panel that helps diagnosis and assessment of autoimmune disease as well. The invention relates also to products used in these methods.

Abstract: The present invention relates to a non-toxic composition containing one or more cysteine compounds selected from L- or D-cysteine, N-acetyl cysteine, and the pharmaceutically acceptable salts thereof, for decreasing the risk of a subject contracting cancer of the stomach, the small intestine and the colon, by locally binding aldehydes present in the stomach, and optionally also separately the aldehydes carried to the small intestine or the colon, or both, whereby the composition is formulated with the help of two or more additives into controlled-release tablets containing at least one additive selected from cationic and gel-forming polymers, which tablets are formed from two or more separate layers with different release profiles, whereby the cysteine compounds are added both into the inner layer(s) and into the tablet material surrounding these.

Abstract: The present invention relates to non-toxic composition containing, as active compounds, one or more aldehyde-binding compounds, such as L- or D-cysteine, N-acetyl cysteine, and the pharmaceutically acceptable salts thereof, and optionally one or more further active compounds selected from sulphites and xylitol, the composition being used for decreasing the risk of a subject contracting cancer of the stomach, and indirectly of the small intestine and the large intestine. The composition is formulated into a controlled-release formulation consisting of granules contained in a capsule.

Abstract: The present invention concerns a non-toxic solid pharmaceutical composition for oral administration, containing one or more cysteine compounds from the group of L-cysteine, D-cysteine and N-acetyl cysteine, combined with one or more additional active agents, at least one of which being selected from cystine, glutathione and methionine, the composition further containing one or more pharmaceutical additives. Further, the invention concerns a method for reducing the incidence of severe headaches, particularly migraine and/or cluster headaches.

Abstract: This invention relates to a non-toxic composition which bind acetaldehyde present in the stomach, intestine and/or colon. The composition comprises one or more acetaldehyde-binding compound(s) comprising one or more free sulphhydryl and/or amino groups. The compound(s) are mixed with a non-toxic carrier that effects sustained release of said compound(s) in the gastrointestinal tract. This invention relates also to food additives and food compositions and packages comprising the composition.

Abstract: The present invention concerns products, such as compositions or medical devices, comprising one or more compounds of the Formula I, containing one or more free sulphhydryl groups, where R1 is hydrogen or an acetyl group, and R2 is a sulphhydryl group or a C1-C5 straight chained or branched hydrocarbon chain, optionally containing one or more heteroatoms selected from O, N and S, further containing one or more free sulphhydryl groups, for use in connection with Helicobacter pylori infections or other related infections, either as such or as combinations with antibiotics, whereby the compound(s) and optionally, when present, the antibiotic(s), are mixed with one or more pharmaceutically acceptable carriers providing sustained local release in the stomach or elsewhere in the upper aerodigestive tract.

Abstract: The object of the invention comprises food compositions, to which one or more acetaldehyde-binding compounds are added. The purpose of the compositions is to reduce the amount of detrimental acetaldehyde in the area of the mouth, the pharynx, the oesophagus, the stomach, and the small and large intestines, and through this, to reduce the risk of developing cancers in these areas.

Abstract: The invention is directed to a method for testing batches of tips for pipettes, the method comprising the steps of calibrating a pipette to be tested with a recommended reference tip, fitting the pipette with a tip to be tested and performing a second calibration and recalibrating the pipette with the reference tip.

Abstract: This invention relates to a method for selecting a plunger-cylinder tip of a pipette and a device for carrying out the method. In the method, the dose size is entered into the control electronics of the pipetting device; the dose size is stored in the control electronics; the amount of doses is entered; and on the basis of the dose size and the amount of doses, the control electronics indicates suitable available interchangeable components on the display.

Abstract: The object of the invention is the use of compounds comprising one or more free sulphhydryl or amino groups for preparing a pharmaceutical composition for locally binding acetaldehyde in saliva, the stomach or the large intestine, and pharmaceutical compositions comprising the said compounds.

Abstract: The present invention relates to the use of a preparation comprising a substance that is capable of binding acetaldehyde, and to the use of a filter that is attached to a tobacco product to reduce tobacco and/or alcohol dependence.

Abstract: This invention relates to a non-toxic composition which bind acetaldehyde present in the stomach, intestine and/or colon. The composition comprises one or more acetaldehyde-binding compound(s) comprising one or more free sulphhydryl and/or amino groups. The compound(s) are mixed with a non-toxic carrier that effects sustained release of said compound(s) in the gastrointestinal tract. This invention relates also to food additives and food compositions and packages comprising the composition.

Abstract: The invention relates to a cigarette holder-type component, which is intended to be attached to a tobacco product and can be adapted to the suction head of the tobacco product so that the smoke travels through the component during smoking. The component contains porous material, into which an aqueous solution containing at least one aldehyde-binding compound has been absorbed to form an aldehyde-binding filter. In the component that is to be attached to the tobacco product, the water content of the material is kept at a level where the aldehyde-binding compounds are capable of reacting with the aldehydes in the smoke, changing them into a harmless form.

Abstract: The object of the invention comprises food compositions, to which one or more acetaldehyde-binding compounds are added. The purpose of the compositions is to reduce the amount of detrimental acetaldehyde in the area of the mouth, the pharynx, the oesophagus, the stomach, and the small and large intestines, and through this, to reduce the risk of developing cancers in these areas.

Abstract: The invention is directed to a method for testing batches of tips for pipettes, the method comprising the steps of calibrating a pipette to be tested with a recommended reference tip, fitting the pipette with a tip to be tested and performing a second calibration and recalibrating the pipette with the reference tip.

Abstract: This invention relates to a non-toxic composition which bind acetaldehyde present in the stomach, intestine and/or colon. The composition comprises one or more acetaldehyde-binding compound(s) comprising one or more free sulphhydryl and/or amino groups. The compound(s) are mixed with a non-toxic carrier that effects sustained release of said compound(s) in the gastrointestinal tract. These compositions are of benefit in particular to patients having atrophic gastritis or achlorhydric or low acid stomach.